Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Dec 30:25:115.
doi: 10.4103/jrms.JRMS_699_19. eCollection 2020.

Effects of venlafaxine on gastrointestinal symptoms, depression, anxiety, stress, and quality of life in patients with the moderate-to-severe irritable bowel syndrome

Mohammad Reza Sharbafchi  1 , Hamid Afshar  1 , Pardis Adhamian  1 , Awat Feizi  2 , Hamed Daghaghzadeh  3   4 , Peyman Adibi  5
Affiliations

Effects of venlafaxine on gastrointestinal symptoms, depression, anxiety, stress, and quality of life in patients with the moderate-to-severe irritable bowel syndrome

Mohammad Reza Sharbafchi et al. J Res Med Sci. .

Abstract

Background: Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder which its treatment is still a question. According to the literature, the use of antidepressants is common for IBS, while its efficacy in this regard is controversial. This study has been raised to assess the efficacy of venlafaxine in IBS patients.

Materials and methods: In this double-blind, randomized clinical trial, 33 patients with moderate-to-severe IBS were included and randomly divided into two groups by using permuted block randomization process of size 4 for each block to receive Venlafaxine or placebo. Venlafaxine in 37.5 mg/day for 2 weeks, followed by 75 mg/day for the next 2 weeks and then 150 mg/day until the end of the study was prescribed. Gastrointestinal symptoms severity, depression, anxiety, stress as main, and quality of life (QoL) as the secondary outcomes were evaluated at the study initiation, within 2, 6, and 12 weeks after treatment and 3 months after intervention cessation.

Results: The gastrointestinal symptoms severity, depression, anxiety, stress, and QoL scores significantly improved in patients who received Venlafaxine but not in placebo group; although after treatment discontinuation they experienced relapse (P < 0.05). Patients treated with venlafaxine experienced significant improvement in IBS symptoms, all three psychological disorders and QoL than placebo group (P < 0.01). The frequency of observed side effects in venlafaxine group including vomiting, nausea, and sleep disturbance was higher than placebo.

Conclusion: Venlafaxine could be considered as an effective treatment for improving gastrointestinal symptoms severity, depression, anxiety, stress, and QoL of patients with IBS. Further studies with larger sample size and longer treatment duration are recommended.

Keywords: Anxiety; depression; irritable bowel syndrome; quality of life; stress; venlafaxine.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Figure 1
Figure 1
Consort diagram of the study population
See this image and copyright information in PMC

References

    1. Drossman DA, Camilleri M, Mayer EA, Whitehead WE. AGA technical review on irritable bowel syndrome. Gastroenterology. 2002;123:2108–31. - PubMed
    1. Sharbafchi MR, Afshar H, Hassanzadeh-Keshteli A, Roohafza H, Daghaghzadeh H, Salehi M, et al. Comparison of stress profiles among individuals with and without functional dyspepsia. Int J Body Mind Culture. 2016;3:46–54.
    1. Solhpour A, Pourhoseingholi MA, Soltani F, Zarghi A, Solhpour A, Habibi M, et al. Gastro-oesophageal reflux disease and irritable bowel syndrome: A significant association in an Iranian population. Eur J Gastroenterol Hepatol. 2008;20:719–25. - PubMed
    1. Jamieson DJ, Steege JF. The prevalence of dysmenorrhea, dyspareunia, pelvic pain, and irritable bowel syndrome in primary care practices. Obstet Gynecol. 1996;87:55–8. - PubMed
    1. North CS, Hong BA, Alpers DH. Relationship of functional gastrointestinal disorders and psychiatric disorders: Implications for treatment. World J Gastroenterol. 2007;13:2020–7. - PMC - PubMed